Identification

Name
Hydrocortisone
Accession Number
DB00741  (APRD01019, DB07886)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. [PubChem]

Structure
Thumb
Synonyms
  • (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
  • (11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
  • 11beta-hydrocortisone
  • 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
  • 11β-hydrocortisone
  • 17-Hydroxycorticosterone
  • 4-Pregnen-11beta,17alpha,21-triol-3,20-dione
  • Cortisol
  • Hidrocortisona
  • Hydrocortisone
  • Hydrocortisonum
  • Kendall's compound F
  • Reichstein's substance M
External IDs
NSC-10483
Product Ingredients
IngredientUNIICASInChI Key
Hydrocortisone aceponate2340UP1L2G74050-20-7MFBMYAOAMQLLPK-FZNHGJLXSA-N
Hydrocortisone acetate3X7931PO7450-03-3ALEXXDVDDISNDU-JZYPGELDSA-N
Hydrocortisone butyrate05RMF7YPWN13609-67-1BMCQMVFGOVHVNG-TUFAYURCSA-N
Hydrocortisone cypionate4XDY25L70B508-99-6DLVOSEUFIRPIRM-KAQKJVHQSA-N
Hydrocortisone phosphate2Y87E22X713863-59-0BGSOJVFOEQLVMH-VWUMJDOOSA-N
Hydrocortisone probutateO6550D6K3A72590-77-3FOGXJPFPZOHSQS-AYVLZSQQSA-N
Hydrocortisone sodium phosphate0388G963HY6000-74-4RYJIRNNXCHOUTQ-OJJGEMKLSA-L
Hydrocortisone sodium succinate50LQB69S1Z125-04-2HHZQLQREDATOBM-CODXZCKSSA-M
Hydrocortisone valerate68717P8FUZ57524-89-7FZCHYNWYXKICIO-FZNHGJLXSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-hydrocort Inj 1000mg/8mlPowder, for solution1 gIntramuscular; IntravenousHospira, Inc.1993-12-312012-08-03Canada
A-hydrocort Inj 100mg/2mlPowder, for solution100 mgIntramuscular; IntravenousHospira, Inc.1992-12-312012-08-03Canada
A-hydrocort Inj 250mg/2mlPowder, for solution250 mgIntramuscular; IntravenousHospira, Inc.1992-12-312012-08-03Canada
A-hydrocort Inj 500mg/4mlPowder, for solution500 mgIntramuscular; IntravenousHospira, Inc.1992-12-312012-08-03Canada
Alocort 1% - CrmCream1 %TopicalUcb Inc1996-12-061998-04-21Canada
Aquacort Lotion 2.5%Lotion2.5 %TopicalMerit Industries Inc.1992-12-312002-05-14Canada
Barriere HC 1%Cream; Jelly1 %TopicalAllen & Hanburys A Glaxo Canada Ltd. Co.1979-12-311998-07-29Canada
Bioelements Immediate ComfortLotion.088 mL/88mLTopicalBioelements2012-08-23Not applicableUs
Cortamed Ont 25 mg/gOintment2.5 %OphthalmicSandoz Canada Incorporated1992-12-31Not applicableCanada
Cortate Crm 1%Cream10 mgTopicalSchering Plough1980-12-312013-07-31Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-hydrocortInjection, powder, lyophilized, for solution100 mg/2mLIntramuscular; IntravenousHospira, Inc.2011-05-122017-08-04Us
Ala ScalpLotion20 mg/mLTopicalCrown Laboratories1973-02-28Not applicableUs
AlacortCream25 mg/gTopicalCrown Laboratories1973-03-09Not applicableUs
AlacortCream10 mg/gTopicalCrown Laboratories1973-03-09Not applicableUs
Anusol HCCream25 mg/gTopicalSalix Pharmaceuticals1984-06-06Not applicableUs
ColocortSuspension100 mg/60mLRectalPaddock Laboratories, Inc.1999-12-31Not applicableUs
Home PapKitCream25 mg/gTopicalInternational Brand Management, Llc2016-09-15Not applicableUs
HydrocortisoneCream25 mg/gTopicalLake Erie Medical Dba Quality Care Produts Llc2006-03-31Not applicableUs
HydrocortisoneCream25 mg/gTopicalPhysicians Total Care, Inc.1995-08-04Not applicableUs
HydrocortisoneCream25 mg/gTopicalAidarex Pharmaceuticals LLC2006-03-31Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
999 Itch RelievingOintment1 g/100gTopicalGuangdong CR. Shunfeng Pharmaceutical Co Ltd1989-07-20Not applicableUs
999 Itch RelievingOintment1 g/100gTopicalGuangdong CR. Shunfeng Pharmaceutical Co Ltd1989-07-20Not applicableUs
Advanced Anti-itch TherapySoap1 g/100gTopicalCVS Health2016-06-10Not applicableUs
Advanced HydrocortisoneCream10 mg/gTopicalUltra Seal Corporation2011-04-05Not applicableUs
Aftate Hydrocortisone CreamCream1 g/100gTopicalSabel Med Llc2016-05-01Not applicableUs
Ana Cool Rapid Soothing Cooling FormulaCream10 mg/gTopicalAna Cool, Llc2015-11-25Not applicableUs
Anti ItchCream1 g/100gTopicalSafeway2005-08-24Not applicableUs
Anti ItchCream1 g/100gTopicalRite Aid2013-09-11Not applicableUs
Anti ItchLotion1 g/100gTopicalWalgreen2012-03-27Not applicableUs
Anti ItchCream1 g/100gTopicalHyvee2015-11-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Anucort-HCSuppository25 mg/1RectalGw Pharmaceuticals Ltd.1990-01-15Not applicableUs
Anucort-HCSuppository25 mg/1RectalA S Medication Solutions1990-01-152017-06-20Us
Anucort-HCSuppository25 mg/1RectalPreferreed Pharmaceuticals Inc.2012-03-12Not applicableUs
Anusol HCSuppository25 mg/1RectalSalix Pharmaceuticals2004-06-01Not applicableUs
GRx HiCortSuppository25 mg/2gRectalGeritrex Llc2015-07-012016-01-01Us
Hemmorex-HCSuppository25 mg/1RectalPreferreed Pharmaceuticals Inc.2017-10-17Not applicableUs
Hemmorex-HCSuppository25 mg/1RectalLaser Pharmaceuticals Llc2013-11-12Not applicableUs
Hemmorex-HCSuppository30 mg/1RectalLaser Pharmaceuticals Llc2013-11-12Not applicableUs
HydrocortisoneShampoo1 g/100mLTopicalDr Marder Skincare Llc2017-06-14Not applicableUs
Hydrocortisone AcetateSuppository25 mg/1RectalPreferreed Pharmaceuticals Inc.2013-08-16Not applicableUs
International/Other Brands
Acticort / Aeroseb HC / Ala-Scalp / Algicirtis / Aquanil HC / Beta-HC / Cetacort / Cortaid / Delacort / Ficortril / Genacort / Glycort / Komed HC / Lacticare HC / Lubricort / Medicort / Meusicort / Micort-HC / Mildison / Nogenic HC / Nutracort / Nystaform-HC / Otocort / Penecort / Permicort / Polcort H / Preparation H Hydrocortisone Cream / Prepcort / Prevex HC / Proctocort / Proctocream / Protocort / Remederm HC / Sanatison / Scalpicin Capilar / Schericur / Sigmacort / Synacort / Systral Hydrocort / Timocort
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acella Hydrocortisone Acetate - Pramoxine SinglesHydrocortisone acetate (2.5 g/100g) + Pramocaine (1 g/100g)CreamTopicalAcella Pharmaceuticals, LLC2010-11-082017-08-17Us
Acetasol HCHydrocortisone (1.1 g/100mL) + Acetic acid (2.41 g/100mL)SolutionAuricular (otic)Actavis Mid Atlantic LLC,2002-09-10Not applicableUs
Actinac PwrHydrocortisone acetate (40 mg) + Allantoin (24 mg) + Chloramphenicol (40 mg) + Nicoboxil (24 mg) + Sulfur (320 mg)PowderTopicalRoussel Canada Inc.1978-12-311996-09-09Canada
Actinac PwsHydrocortisone acetate (40 mg) + Allantoin (24 mg) + Chloramphenicol (40 mg) + Nicoboxil (24 mg) + Sulfur (320 mg)Powder, for solutionTopicalHoechst Roussel Canada Inc.1994-12-312001-07-20Canada
Ala QuinHydrocortisone (5 mg/g) + Clioquinol (30 mg/g)CreamTopicalCrown Laboratories1970-08-19Not applicableUs
AlcortinHydrocortisone (2 g/100g) + Diiodohydroxyquinoline (1 g/100g)GelTopicalPrimus Pharmaceuticals2003-07-25Not applicableUs
Alcortin AHydrocortisone acetate (20 mg/g) + Aloe Polysaccharide (10 mg/g) + Diiodohydroxyquinoline (10 mg/g)GelTopicalNovum Pharma, Llc2015-03-01Not applicableUs
AlocaneHydrocortisone acetate (5 mg/mL) + Lidocaine hydrochloride (945 mg/mL)OintmentTopicalProduct Quest2014-11-11Not applicableUs
Ana-LexHydrocortisone acetate (20 mg/g) + Lidocaine hydrochloride (20 mg/g)CreamTopicalAvion Pharmaceuticals, Llc2008-02-28Not applicableUs
Analpram AdvancedHydrocortisone acetate + Pramoxine hydrochlorideKitFerndale Laboratories, Inc.2010-10-012016-04-30Us
Categories
UNII
WI4X0X7BPJ
CAS number
50-23-7
Weight
Average: 362.4599
Monoisotopic: 362.20932407
Chemical Formula
C21H30O5
InChI Key
JYGXADMDTFJGBT-VWUMJDOOSA-N
InChI
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

Structured Indications
Pharmacodynamics

Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

Mechanism of action

Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
AAnnexin A1
agonist
Human
UCorticosteroid 11-beta-dehydrogenase isozyme 2Not AvailableHuman
U3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1Not AvailableHuman
Absorption

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding

95%

Metabolism

Primarily hepatic via CYP3A4

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half life

6-8 hours

Clearance
Not Available
Toxicity

Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydrocortisone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrocortisone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Hydrocortisone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Hydrocortisone.Approved, Experimental, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Hydrocortisone.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Hydrocortisone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrocortisone.Experimental, Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Hydrocortisone.Approved, Withdrawn
AldesleukinHydrocortisone may decrease the antineoplastic activities of Aldesleukin.Approved
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Hydrocortisone.Investigational
AlmasilateThe bioavailability of Hydrocortisone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Hydrocortisone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone.Approved
AloglutamolThe bioavailability of Hydrocortisone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Hydrocortisone.Experimental
AluminiumThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Hydrocortisone.Approved
AmiodaroneThe metabolism of Hydrocortisone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BHydrocortisone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Hydrocortisone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Hydrocortisone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Hydrocortisone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Hydrocortisone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Hydrocortisone.Approved, Investigational
AprepitantThe serum concentration of Hydrocortisone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone.Approved, Investigational
AtazanavirThe metabolism of Hydrocortisone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Hydrocortisone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Hydrocortisone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Hydrocortisone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Hydrocortisone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrocortisone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Hydrocortisone.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydrocortisone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Hydrocortisone.Experimental
BendroflumethiazideHydrocortisone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Hydrocortisone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Hydrocortisone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Hydrocortisone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Hydrocortisone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Hydrocortisone.Experimental
Bismuth SubcitrateThe bioavailability of Hydrocortisone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Hydrocortisone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Hydrocortisone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Hydrocortisone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Hydrocortisone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Hydrocortisone.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrocortisone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Hydrocortisone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Hydrocortisone.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Hydrocortisone.Experimental
BumetanideHydrocortisone may increase the hypokalemic activities of Bumetanide.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Hydrocortisone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Hydrocortisone can be decreased when combined with Calcium silicate.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocortisone.Approved
Capromab pendetideHydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydrocortisone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Hydrocortisone.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Hydrocortisone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Hydrocortisone.Approved, Investigational
CeritinibThe serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Hydrocortisone.Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Hydrocortisone.Approved, Vet Approved
ChlorothiazideHydrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone.Approved
ChlorthalidoneHydrocortisone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Hydrocortisone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrocortisone.Experimental
CinoxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Hydrocortisone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Hydrocortisone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Hydrocortisone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Hydrocortisone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Hydrocortisone can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Hydrocortisone.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Hydrocortisone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Hydrocortisone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Hydrocortisone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Hydrocortisone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Hydrocortisone.Investigational
CyclopenthiazideHydrocortisone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Hydrocortisone.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone.Approved
DabrafenibThe serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Hydrocortisone can be increased when it is combined with Daidzein.Experimental
DanazolHydrocortisone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe metabolism of Hydrocortisone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Hydrocortisone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Hydrocortisone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Hydrocortisone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Hydrocortisone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Hydrocortisone.Approved, Vet Approved
DienestrolThe serum concentration of Hydrocortisone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Hydrocortisone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Hydrocortisone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Hydrocortisone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Hydrocortisone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Hydrocortisone.Experimental
DihydroergotamineThe metabolism of Hydrocortisone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneHydrocortisone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Hydrocortisone can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Donepezil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Hydrocortisone.Approved, Investigational
DoxycyclineThe metabolism of Hydrocortisone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Hydrocortisone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Hydrocortisone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrocortisone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Hydrocortisone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Hydrocortisone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Echothiophate.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Hydrocortisone.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Edrophonium.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Hydrocortisone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Hydrocortisone.Approved
EquolThe serum concentration of Hydrocortisone can be increased when it is combined with Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Hydrocortisone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Hydrocortisone.Approved
ErythromycinThe metabolism of Hydrocortisone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Hydrocortisone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Hydrocortisone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Hydrocortisone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Hydrocortisone can be increased when it is combined with Estrone.Approved
Etacrynic acidHydrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Hydrocortisone.Experimental
Ethinyl EstradiolThe serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Hydrocortisone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Hydrocortisone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Hydrocortisone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Hydrocortisone.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Hydrocortisone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Hydrocortisone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Hydrocortisone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Hydrocortisone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Hydrocortisone.Approved
FenthionThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Hydrocortisone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Hydrocortisone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Hydrocortisone.Experimental
FingolimodHydrocortisone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Hydrocortisone.Approved, Withdrawn
FluconazoleThe metabolism of Hydrocortisone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Hydrocortisone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Hydrocortisone.Experimental
FluoxymesteroneHydrocortisone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Hydrocortisone.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Hydrocortisone.Approved
FluvoxamineThe metabolism of Hydrocortisone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Hydrocortisone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Hydrocortisone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Hydrocortisone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideHydrocortisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Hydrocortisone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Hydrocortisone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Hydrocortisone is combined with GI-5005.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrocortisone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone.Approved, Investigational
GLPG-0492Hydrocortisone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrocortisone.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Hydrocortisone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Hydrocortisone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydrocortisone.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Hydrocortisone.Experimental
HexestrolThe serum concentration of Hydrocortisone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Hydrocortisone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.Approved, Investigational
HydrochlorothiazideHydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydrocortisone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Hydrocortisone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Hydrocortisone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Hydrocortisone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Hydrocortisone.Approved
ImatinibThe metabolism of Hydrocortisone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Hydrocortisone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Hydrocortisone.Approved
IndapamideHydrocortisone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Hydrocortisone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Hydrocortisone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Hydrocortisone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Hydrocortisone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrocortisone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrocortisone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Hydrocortisone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Hydrocortisone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Hydrocortisone.Withdrawn
IsradipineThe metabolism of Hydrocortisone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Hydrocortisone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Hydrocortisone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Hydrocortisone.Experimental
KetoconazoleThe metabolism of Hydrocortisone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Hydrocortisone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Hydrocortisone.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Hydrocortisone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrocortisone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrocortisone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Hydrocortisone.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Hydrocortisone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Hydrocortisone.Experimental
LopinavirThe metabolism of Hydrocortisone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Hydrocortisone.Approved, Investigational
LovastatinThe metabolism of Hydrocortisone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Hydrocortisone.Approved, Investigational
LuliconazoleThe serum concentration of Hydrocortisone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Hydrocortisone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Hydrocortisone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Hydrocortisone.Illicit, Investigational, Withdrawn
MagaldrateThe bioavailability of Hydrocortisone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Hydrocortisone.Approved
Magnesium silicateThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Hydrocortisone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Hydrocortisone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Hydrocortisone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone.Approved
MesteroloneHydrocortisone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Hydrocortisone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Hydrocortisone.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Hydrocortisone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.Approved
MethallenestrilThe serum concentration of Hydrocortisone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideHydrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydrocortisone.Approved
MethyltestosteroneHydrocortisone may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Hydrocortisone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Metoclopramide.Approved, Investigational
MetolazoneHydrocortisone may increase the hypokalemic activities of Metolazone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Hydrocortisone.Experimental
MifepristoneThe serum concentration of Hydrocortisone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrocortisone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Hydrocortisone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
MitotaneThe serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Hydrocortisone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Hydrocortisone.Experimental
MoxestrolThe serum concentration of Hydrocortisone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hydrocortisone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Hydrocortisone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Hydrocortisone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Hydrocortisone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Hydrocortisone.Approved
NandroloneHydrocortisone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateHydrocortisone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Hydrocortisone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
NefazodoneThe metabolism of Hydrocortisone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Hydrocortisone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Hydrocortisone.Approved
NetupitantThe serum concentration of Hydrocortisone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Hydrocortisone can be decreased when it is combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Hydrocortisone.Approved, Investigational
NicorandilThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Hydrocortisone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Hydrocortisone.Approved
NilotinibThe metabolism of Hydrocortisone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Hydrocortisone.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Hydrocortisone.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hydrocortisone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Norfloxacin.Approved
OlaparibThe metabolism of Hydrocortisone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Hydrocortisone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Hydrocortisone.Vet Approved
OsimertinibThe serum concentration of Hydrocortisone can be increased when it is combined with Osimertinib.Approved
OxandroloneHydrocortisone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Hydrocortisone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Oxolinic acid.Experimental
OxymetholoneHydrocortisone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Hydrocortisone.Approved, Withdrawn
PalbociclibThe serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Hydrocortisone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Hydrocortisone.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Hydrocortisone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Hydrocortisone.Approved, Investigational, Vet Approved, Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrocortisone.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Hydrocortisone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Hydrocortisone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Hydrocortisone.Approved, Investigational
PhenytoinThe serum concentration of Hydrocortisone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrocortisone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pipemidic acid.Experimental
PiretanideHydrocortisone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Hydrocortisone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Hydrocortisone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Hydrocortisone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Hydrocortisone.Approved
Polyestradiol phosphateThe serum concentration of Hydrocortisone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideHydrocortisone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Hydrocortisone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Hydrocortisone.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone.Approved
PrimidoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Hydrocortisone.Experimental
PromestrieneThe serum concentration of Hydrocortisone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Hydrocortisone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Hydrocortisone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Hydrocortisone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Hydrocortisone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Hydrocortisone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Hydrocortisone can be increased when it is combined with Quinestrol.Approved
QuinethazoneHydrocortisone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Hydrocortisone.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Hydrocortisone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Hydrocortisone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Hydrocortisone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Hydrocortisone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Hydrocortisone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Hydrocortisone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Hydrocortisone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrocortisone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Hydrocortisone.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Hydrocortisone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Hydrocortisone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Hydrocortisone.Approved
SaquinavirThe metabolism of Hydrocortisone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortisone.Approved
SecoisolariciresinolThe serum concentration of Hydrocortisone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Hydrocortisone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Hydrocortisone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Hydrocortisone.Investigational
SildenafilThe metabolism of Hydrocortisone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Hydrocortisone.Approved
SiltuximabThe serum concentration of Hydrocortisone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Hydrocortisone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Hydrocortisone.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrocortisone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydrocortisone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Hydrocortisone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Hydrocortisone.Investigational
St. John's WortThe serum concentration of Hydrocortisone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololHydrocortisone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Hydrocortisone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone.Approved
SulfisoxazoleThe metabolism of Hydrocortisone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Hydrocortisone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrocortisone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Hydrocortisone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Hydrocortisone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydrocortisone.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Hydrocortisone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Hydrocortisone.Approved, Withdrawn
TelithromycinThe metabolism of Hydrocortisone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Hydrocortisone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Hydrocortisone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Hydrocortisone.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Hydrocortisone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Hydrocortisone.Approved
TestosteroneHydrocortisone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateHydrocortisone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Hydrocortisone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Hydrocortisone.Approved
TiboloneThe serum concentration of Hydrocortisone can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Hydrocortisone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Hydrocortisone.Investigational
TocilizumabThe serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibHydrocortisone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Hydrocortisone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Hydrocortisone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Hydrocortisone.Approved, Investigational
TorasemideHydrocortisone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Hydrocortisone.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Hydrocortisone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Hydrocortisone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trichlorfon.Vet Approved
TrichlormethiazideHydrocortisone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Hydrocortisone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrocortisone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.Approved
TromethamineThe bioavailability of Hydrocortisone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Hydrocortisone.Approved, Investigational, Nutraceutical
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Hydrocortisone.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Zoster vaccine.Approved
VenlafaxineThe metabolism of Hydrocortisone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Hydrocortisone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrocortisone.Approved, Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Hydrocortisone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrocortisone.Approved, Investigational
VoriconazoleThe metabolism of Hydrocortisone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinHydrocortisone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Hydrocortisone.Approved, Investigational
ZeranolThe serum concentration of Hydrocortisone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Hydrocortisone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Hydrocortisone.Withdrawn
Food Interactions
  • Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.

References

Synthesis Reference

Manfred Baumgarth, Dieter Orth, Jurgen Harting, Hans Schaefer, Achim Zesch, "Hydrocortisone orthoesters, pharmaceutical formulations thereof and processes for the preparation thereof." U.S. Patent US4264584, issued March, 1974.

US4264584
General References
  1. de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. [PubMed:12932892]
  2. Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31. [PubMed:6461917]
  3. KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81. [PubMed:13233328]
External Links
Human Metabolome Database
HMDB14879
KEGG Drug
D00088
KEGG Compound
C00735
PubChem Compound
5754
PubChem Substance
46505089
ChemSpider
5551
BindingDB
13775
ChEBI
17650
ChEMBL
CHEMBL389621
Therapeutic Targets Database
DAP000718
PharmGKB
PA449905
IUPHAR
2868
Guide to Pharmacology
GtP Drug Page
HET
HCY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Hydrocortisone
ATC Codes
S03CA04 — Hydrocortisone and antiinfectivesS01CB03 — HydrocortisoneS01CA03 — Hydrocortisone and antiinfectivesS02BA01 — HydrocortisoneD07AA02 — HydrocortisoneD07BB04 — Hydrocortisone butyrate and antisepticsS02CA03 — Hydrocortisone and antiinfectivesD07AB02 — Hydrocortisone butyrateC05AA01 — HydrocortisoneD07AC16 — Hydrocortisone aceponateD07BA04 — Hydrocortisone and antisepticsS01BB01 — Hydrocortisone and mydriaticsA01AC03 — HydrocortisoneS01BA02 — HydrocortisoneD07CA01 — Hydrocortisone and antibioticsH02AB09 — HydrocortisoneD07XA01 — HydrocortisoneR01AD60 — Hydrocortisone, combinationsA07EA02 — Hydrocortisone
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 56:36.00 — Anti-inflammatory Agents
PDB Entries
2v95 / 2vdy / 4c49 / 4p6x / 5hgc
FDA label
Download (30 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingOtherInsulin Resistance1
0CompletedTreatmentFibromyalgia1
0Not Yet RecruitingBasic ScienceHuman Immunodeficiency Virus (HIV)1
0RecruitingBasic ScienceDepression1
0RecruitingBasic ScienceHealthy Volunteers1
1Active Not RecruitingBasic ScienceBMI >30 kg/m21
1Active Not RecruitingTreatmentRotator Cuff Tear - Partial Thickness1
1CompletedNot AvailableInfection NOS1
1CompletedNot AvailableRelative Adrenal Insufficiency / Sepsis1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers / Inflammatory Reaction / Pain1
1CompletedOtherAdrenal Insufficiency1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentAdrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH)1
1CompletedTreatmentArterial Hypotension / Blood Pressures / Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants1
1CompletedTreatmentErythemas / Pain1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentKnee Osteoarthritis (Knee OA)1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentPsoriasis Vulgaris1
1Not Yet RecruitingTreatmentAdrenal Insufficiency2
1RecruitingBasic ScienceDiabetes, Diabetes Mellitus Type 11
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1RecruitingTreatmentColorectal Cancers / Head and Neck Carcinoma1
1RecruitingTreatmentHeroin Dependence / Opioid Use Disorders1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1Unknown StatusTreatmentOvarian Epithelial Cancer1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedDiagnosticSystemic Lupus Erythematosus (SLE)1
1, 2CompletedTreatment21-Hydroxylase Deficiency / Adrenogenital Syndrome / Congenital Adrenal Hyperplasia (CAH)1
1, 2CompletedTreatmentCardiac Arrest1
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAddison's Disease / Adrenal Hyperplasia Congenital1
1, 2RecruitingTreatmentInhospital Cardiac Arrest1
1, 2TerminatedBasic ScienceRenin Angiotensin1
1, 2TerminatedTreatmentAdenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage III Prostate Cancer / Stage IV Prostate Cancer1
1, 2TerminatedTreatmentAnaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma1
1, 2TerminatedTreatmentProstate Cancer1
2Active Not RecruitingSupportive CareDermatologic Complications / Neoplasms, Malignant1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedNot AvailablePostoperative Complications / Postoperative Pancreatitis1
2CompletedPreventionChronic Lung Disease of Prematurity1
2CompletedPreventionChronic Lung Disease of Prematurity / Encephalomalacia / Premature Births1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Multiple Organ Failure1
2CompletedTreatmentAdenocarcinoma, Prostate / Prostate Cancer1
2CompletedTreatmentAdrenal Hyperplasia, Congenital1
2CompletedTreatmentAdrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH) / Excess Androgen1
2CompletedTreatmentAngioedema1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBlood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2CompletedTreatmentCardiac Output, Low1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentHemorrhoids1
2CompletedTreatmentJet Lag Syndrome1
2CompletedTreatmentLeukemia, Mast-Cell / Lymphoma, Mantle-Cell1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
2CompletedTreatmentOpioid Dependence1
2CompletedTreatmentPaediatric Sepsis / Pediatric Sepsis / Sepsis1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentPrurigo Nodularis1
2CompletedTreatmentRash1
2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia1
2Not Yet RecruitingBasic ScienceAdolescent Development / Borderline Personality Disorder (BPD)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)1
2Not Yet RecruitingTreatmentCritically Ill / Shock, Septic / Vasoplegic Syndrome1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAdrenal Hyperplasia, Congenital1
2RecruitingTreatmentApomorphine-induced Skin Reactions / Parkinson's Disease (PD)1
2RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentPhobic Disorders1
2Unknown StatusTreatmentAddison's Disease1
2Unknown StatusTreatmentCirrhosis With Ascites1
2Unknown StatusTreatmentInjuries, Whiplash1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3CompletedPreventionInjuries, Multiple1
2, 3CompletedTreatmentAddison's Disease1
2, 3CompletedTreatmentAdrenal Insufficiency1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3RecruitingTreatmentAsphyxia / Hypoxic-Ischaemic Encephalopathy1
2, 3Unknown StatusTreatmentMortality / Ventilations, Mechanical1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentCardiovascular Insufficiency / Infant, Newborn, Diseases1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Malignant Lymphomas1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3CompletedTreatmentAlcohol Craving / Stress, Physiological / Stress, Psychological1
3CompletedTreatmentAlopecia Areata (AA)1
3CompletedTreatmentCardiac Arrest1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChronic Lung Disease of Prematurity1
3CompletedTreatmentCoagulation Dysfunction in Septic Shock / Hemodynamic Improvement Induced by Hydrocortisone1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHerpes Labialis1
3CompletedTreatmentLeukemias / Malignant Lymphomas1
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
3CompletedTreatmentNeonatal Hypotension1
3CompletedTreatmentOral Submucous Fibrosis1
3CompletedTreatmentOtitis Externa1
3CompletedTreatmentPatient Admitted in Reanimation1
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentPsoriasis Vulgaris1
3CompletedTreatmentSepsis / Shock, Septic1
3CompletedTreatmentSevere Sepsis1
3CompletedTreatmentShock, Septic3
3Not Yet RecruitingTreatmentImmune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic1
3RecruitingPreventionChronic Lung Disease of Prematurity / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Very Low Birth Weight Infant1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)2
3RecruitingTreatmentLiver Cirrhosis1
3RecruitingTreatmentSevere Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3TerminatedTreatmentEvidence of Liver Transplantation / Transplantations1
3TerminatedTreatmentInfluenza in Humans / Viral Pneumonia1
3TerminatedTreatmentProstatic Neoplasms1
3Unknown StatusTreatmentLow Back Pain (LBP)1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4Active Not RecruitingTreatmentShock, Septic1
4CompletedNot AvailableMinor burns1
4CompletedBasic ScienceFeeling Anxious1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceStress Disorders, Posttraumatic1
4CompletedPreventionPostoperative Inflammatory Response1
4CompletedPreventionPosttraumatic Stress Disorders / Systemic Inflammatory Response Syndrome (SIRS)1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdrenal Insufficiency1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentAtopic Dermatitis (AD) / Psoriasis1
4CompletedTreatmentCoronary Artery Disease / Mitral Valve Regurgitation1
4CompletedTreatmentHip Injuries1
4CompletedTreatmentHyperglycemias1
4CompletedTreatmentKnee Replacement Surgery1
4CompletedTreatmentShock1
4CompletedTreatmentSnake Bites1
4Enrolling by InvitationTreatmentAdrenal Insufficiency1
4Enrolling by InvitationTreatmentGranuloma / Tracheostomy care1
4Not Yet RecruitingTreatmentUlcerative Colitis (UC)1
4RecruitingPreventionNeoplasms, Pancreatic / Pancreatic Fistula1
4RecruitingSupportive CareRheumatoid Arthritis1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingTreatmentCritical Illness / Fluid Overload / Sepsis / Shock, Septic1
4RecruitingTreatmentFunction of Renal Transplant1
4RecruitingTreatmentGranulomatous Mastitis1
4RecruitingTreatmentUlcerative Colitis (UC)1
4TerminatedNot AvailableAsthma Bronchial1
4TerminatedTreatmentPartial Corticotrope Insufficiency1
4TerminatedTreatmentShock, Septic1
4Unknown StatusTreatmentAcute Respiratory Distress Syndrome (ARDS) / Adrenal Insufficiency1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentPituitary Neoplasms / Postsurgical craniopharyngioma1
4WithdrawnTreatmentAdrenal Insufficiency / Sepsis1
4WithdrawnTreatmentAtopic Dermatitis (AD)1
4WithdrawnTreatmentPhimosis1
4WithdrawnTreatmentPost-Traumatic Stress Disorder (PTSD)1
Not AvailableActive Not RecruitingSupportive CareSjögren's Syndrome1
Not AvailableCompletedNot AvailableAnxiety Disorders / Major Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableDependence, Cocaine1
Not AvailableCompletedNot AvailableHeroin Dependence / Learning and Memory1
Not AvailableCompletedNot AvailableKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedNot AvailableSepsis1
Not AvailableCompletedBasic ScienceIntrusive Memories1
Not AvailableCompletedBasic SciencePosttraumatic Stress Disorders1
Not AvailableCompletedPreventionFevers / Hemodynamics Instability / Hypothermia / Idiopathic orthostatic hypotension1
Not AvailableCompletedScreeningOther Diseases or Conditions1
Not AvailableCompletedTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Severe Sepsis / Shock, Septic1
Not AvailableCompletedTreatmentAddison's Disease1
Not AvailableCompletedTreatmentAddison's Disease / BMI >30 kg/m21
Not AvailableCompletedTreatmentAdrenal Hyperplasia, Congenital1
Not AvailableCompletedTreatmentAtopic Dermatitis (AD)1
Not AvailableCompletedTreatmentHeart Arrest1
Not AvailableCompletedTreatmentHeart Disease Congenital Complex1
Not AvailableCompletedTreatmentPTSD1
Not AvailableCompletedTreatmentPhobic Disorders1
Not AvailableCompletedTreatmentPituitary Adenomas / Pituitary Diseases1
Not AvailableCompletedTreatmentTotal Hip Replacement1
Not AvailableNot Yet RecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome2
Not AvailableRecruitingBasic ScienceBorderline Personality Disorder (BPD) / PTSD1
Not AvailableRecruitingPreventionPost Traumatic Stress Disorder (PTSD)1
Not AvailableRecruitingTreatmentAtopic Dermatitis (AD)1
Not AvailableRecruitingTreatmentFatty Acids, Nonesterified / Hydrocortisone / Hypopituitarism / Insulin Sensitivity / Lipids1
Not AvailableRecruitingTreatmentIntussusception1
Not AvailableRecruitingTreatmentPlantar fascial fibromatosis1
Not AvailableRecruitingTreatmentShock, Septic1
Not AvailableSuspendedNot AvailableSome Studies Shows That the Steroid Can Reduce the Injury of the I/R of the Liver1
Not AvailableTerminatedNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableTerminatedPreventionBrain Death1
Not AvailableTerminatedTreatmentNecrotizing Enterocolitis1
Not AvailableTerminatedTreatmentPosttraumatic Stress Disorders1
Not AvailableUnknown StatusPreventionPosttraumatic Stress Disorders1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentPTSD1
Not AvailableWithdrawnTreatmentPost-Traumatic Stress Disorder (PTSD)1

Pharmacoeconomics

Manufacturers
  • Hi tech pharmacal co inc
  • Allergan herbert div allergan inc
  • Del ray laboratories inc
  • Salix pharmaceuticals inc
  • Bayer pharmaceuticals corp
  • Monarch pharmaceuticals inc
  • Valeant pharmaceuticals international
  • Westwood squibb pharmaceuticals inc
  • C and m pharmacal inc
  • Pharmaceutical assoc inc div beach products
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Altana inc
  • Ambix laboratories div organics corp america
  • Everylife
  • E fougera div altana inc
  • G and w laboratories inc
  • Ingram pharmaceutical co
  • Ivax pharmaceuticals inc
  • Naska pharmacal co inc div rugby darby group cosmetics
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Stiefel laboratories inc
  • Syosset laboratories inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Topiderm inc
  • Usl pharma inc
  • Vintage pharmaceuticals inc
  • Whiteworth towne paulsen inc
  • Sanofi aventis us llc
  • Coria laboratories ltd
  • Medicis pharmaceutical corp
  • Paddock laboratories inc
  • Ani pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Healthpoint ltd
  • Allergan herbert skin care div allergan inc
  • Pharmacia and upjohn co
  • Baker norton pharmaceuticals inc
  • Solvay pharmaceuticals
  • Beta dermaceuticals inc
  • Bluline laboratories inc
  • Heran pharmaceutical inc
  • Mericon industries inc
  • Perrigo co
  • Pfizer global research development
  • Carolina medical products co
  • Dermik laboratories div aventis pharmaceuticals inc
  • Torch laboratories inc
  • X gen pharmaceuticals inc
  • Jsj pharmaceuticals llc
  • Pfizer laboratories div pfizer inc
  • Barr laboratories inc
  • Elkins sinn div ah robins co inc
  • John j ferrante
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Nexgen pharma inc
  • Panray corp sub ormont drug and chemical co inc
  • Parke davis div warner lambert co
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Stiefel a gsk co
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Merck and co inc
  • Pfipharmecs div pfizer inc
  • Schwarz pharma inc
  • Able laboratories inc
  • Hr cenci laboratories inc
  • Ferndale laboratories inc
  • Akorn inc
  • Bel mar laboratories inc
  • Colgate oral pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Triax pharmaceuticals llc
  • Yamanouchi europe bv
  • Savage laboratories inc div altana inc
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories hosp products div
  • Hospira inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • International medication systems ltd
  • Taro pharmaceuticals inc
  • Ranbaxy laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous100 mg/2mL
PowderTopical
Powder, for solutionTopical
SoapTopical1 g/100g
LotionTopical20 mg/mL
CreamTopical1 %
Kit
SuppositoryRectal
OintmentRectal; Topical
CreamTopical5 mg/g
SolutionTopical1 g/100g
OintmentTopical1.02 g/100g
Cream; jellyTopical1 %
LotionTopical.088 mL/88mL
CreamTopical.01 g/g
CreamTopical1 g/g
CreamTopical10 mg/g
SuspensionAuricular (otic)
SprayTopical1 g/100g
CreamTopical0.5 %
SprayTopical10 g/mL
OintmentOphthalmic2.5 %
OintmentTopical10 mg
TabletOral10 mg
TabletOral20 mg
EnemaRectal100 mg
EnemaRectal100 mg/60mL
Enema; suspensionRectal100 mg
OintmentTopical100 g/g
CreamTopical1 mg
Aerosol, foamRectal10 %
Aerosol, foamRectal1500 mg/15g
Aerosol, foamTopical1500 mg/15g
SuppositoryRectal10 mg
SuppositoryRectal40 mg
SuspensionTopical
OintmentTopical10 mg/g
GelTopical10 mg/g
LiquidTopical10 mg/mL
LotionTopical1 g/100g
LotionTopical10 mg/g
GelTopical1 mg/g
LotionTopical1 mg/mL
LotionTopical1.18 mL/118mL
LotionTopical.75 g/100mL
CreamTopical.284 g/28.4g
CreamTopical.284 g/287.4g
CreamTopical1 g/100mL
CreamTopical2.5 %
SolutionTopical2.5 %
KitOral
OintmentTopical10 mg/mL
OintmentTopical1 mL/100mL
LotionTopical1 g/mL
CreamTopical.5 g/100g
SuppositoryRectal.025 g/2g
SuppositoryRectal25 mg/2g
Lotion / shampooTopical5 mg/mL
ShampooTopical5 mg/mL
Aerosol, sprayTopical1.13 g/113g
CreamTopical1 h/100g
CreamTopical10 mg/mL
CreamTopical25 mg/g
GelTopical1 g/100g
LotionTopical25 mg/mL
OintmentTopical25 mg/1
OintmentTopical25 mg/g
OintmentTopical5 mg/g
ShampooTopical1 g/100mL
SuspensionRectal100 mg/60mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
OintmentTopical1.12 g/100g
SuppositoryRectal25 mg/1
SuppositoryRectal30 mg/1
SolutionAuricular (otic)
CreamTopical1 mg/g
OintmentTopical1 mg/g
SolutionTopical1 mg/mL
CreamTopical500 mg
CreamTopical1 g
CreamTopical1.02 g/100g
CreamTopical5 mg
CreamTopical10 mg
OintmentTopical0.5 %
OintmentTopical1 %
Powder, for solutionIntramuscular; Intravenous100 mg
Powder, for solutionIntramuscular; Intravenous250 mg
Powder, for solutionIntramuscular; Intravenous500 mg
Powder, for solutionIntramuscular; Intravenous1 g
CreamTopical140 mg/14g
CreamTopical2 mg/g
OintmentTopical2 mg/g
LotionTopical1 g/100mL
CreamTopical0.2 %
OintmentTopical0.2 %
LotionTopical1 g/88mL
CreamTopical1 g/100g
OintmentTopical1 g/100g
CreamTopical.5 %
CreamRectal
CreamRectal; Topical
GelRectal
LiquidTopical5 mg/mL
LiquidTopical9 mg/mL
SprayTopical10 mg/mL
CreamTopical.009 g/1
SuspensionAuricular (otic); Ophthalmic
Solution / dropsAuricular (otic)
Suspension / dropsAuricular (otic)
OintmentOphthalmic
SuspensionOphthalmic
LotionTopical5 mg/g
LotionTopical20 mg/g
Kit
LotionTopical.025 mg/2.5mL
GelTopical
CreamTopical7.5 g/100mL
LotionTopical
OintmentTopical
CreamTopical
LiquidTopical.28 mg/100mL
AerosolRectal
Aerosol, foamTopical
OintmentRectal
OintmentRectal; Topical750 mg
CreamTopical.51 g/100g
CreamTopical1 mg/100mL
LotionTopical2.5 %
LiquidTopical10 mg/g
LiquidTopical
LiquidTopical1 g/100mL
Injection, powder, for solutionIntramuscular; Intravascular100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous1000 mg/8mL
Injection, powder, for solutionIntramuscular; Intravenous250 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
LotionTopical1 mL/100mL
OintmentAuricular (otic); Ophthalmic
Solution / dropsOphthalmic
SolutionTopical25 mg/mL
LotionTopical1 %
CreamTopical2 %
CreamTopical280 mg/28g
CreamTopical1.12 g/100g
CreamTopical10 mg/L
SprayTopical10 g/L
Prices
Unit descriptionCostUnit
Locoid Lipocream 0.1% Cream 60 gm Tube335.36USD tube
Cortifoam 90 mg Foam 15 gm Can239.99USD can
Locoid 0.1% Solution 60ml Bottle233.15USD bottle
Locoid Lipocream 0.1% Cream 45 gm Tube200.98USD tube
Locoid 0.1% Cream 45 gm Tube183.83USD tube
Locoid 0.1% Ointment 45 gm Tube174.86USD tube
Pandel 0.1% Cream 45 gm Tube161.37USD tube
Pandel 0.1% Cream 15 gm Tube138.56USD tube
Proctocort 1% Cream 28.35 gm Tube127.51USD tube
Anusol-HC 2.5% Cream 30 gm Tube106.45USD tube
Locoid Lipocream 0.1% Cream 15 gm Tube85.41USD tube
Texacort 2.5% Solution 30ml Bottle85.41USD bottle
Cortisporin 3.5-10000-1 Solution 10ml Bottle84.33USD bottle
Proctofoam HC 1-1% Foam 10 gm Can81.9USD can
Cortisporin 3.5-10000-1 Suspension 10ml Bottle79.55USD bottle
Locoid 0.1% Solution 20ml Bottle79.28USD bottle
Cortisporin 1% Ointment 15 gm Tube75.09USD tube
Locoid 0.1% Cream 15 gm Tube67.49USD tube
Hydrocortisone Ace-Pramoxine 2.5-1% Cream 28.35 gm Tube64.75USD tube
Locoid 0.1% Ointment 15 gm Tube62.04USD tube
Hydrocortisone Valerate 0.2% Ointment 60 gm Tube56.74USD tube
Hydrocortisone 2.5% Lotion 59 gm Bottle55.61USD bottle
Westcort 0.2% Ointment 60 gm Tube55.0USD tube
Cortisporin 0.5-0.5-10000 Cream 7.5 gm Tube54.37USD tube
Westcort 0.2% Ointment 15 gm Tube50.99USD tube
Hydrocortisone Butyrate 0.1% Cream 45 gm Tube49.43USD tube
Hydrocortisone Valerate 0.2% Ointment 45 gm Tube48.73USD tube
Hydrocortisone 2.5% Lotion 59ml Bottle47.47USD bottle
Westcort 0.2% Ointment 45 gm Tube46.97USD tube
Hydrocortisone Valerate 0.2% Cream 60 gm Tube44.99USD tube
Hydrocortisone Valerate 0.2% Cream 45 gm Tube33.99USD tube
Ala Scalp 2% Lotion 29.6ml Bottle30.99USD bottle
Hydrocortisone Valerate 0.2% Ointment 15 gm Tube30.56USD tube
Westcort 0.2% Cream 15 gm Tube25.99USD tube
Hydrocortisone Valerate 0.2% Cream 15 gm Tube19.99USD tube
Cortisporin eye drops19.74USD ml
Solu-Cortef 1 g/vial17.55USD vial
Hydrocortisone 1% Lotion 118ml Bottle15.99USD bottle
Hydrocortisone Acetate 12 25 mg Suppository Box15.01USD box
Hydrocortisone 2.5% Ointment 28.35 gm Tube13.68USD tube
Hydrocortisone 2.5% Cream 30 gm Tube13.67USD tube
Colocort 100 mg/60ml Enema 60ml Bottle13.15USD bottle
Hydrocortisone 100 mg/60ml Enema 60ml Bottle12.6USD bottle
Hydrocortisone 0.5% Cream 28.35 gm Tube11.99USD tube
Hydrocortisone 1% Cream 15 gm Tube11.99USD tube
Hydrocortisone 1% Cream 28 gm Tube11.99USD tube
Hydrocortisone Acetate 1-1% Ointment 30 gm Tube11.99USD tube
Solu-Cortef 500 mg/vial10.47USD vial
Hydrocortisone hemisucc powder9.9USD g
Cortifoam 10% aerosol9.35USD g
Hydrocortisone Sod. Succinate 1 g/vial9.01USD vial
Solu-cortef (pf) 250 mg vial8.58USD vial
Cortisporin-tc ear susp8.3USD ml
Cortisporin ear suspension7.86USD ml
Solu-Cortef 250 mg/vial7.05USD vial
Cortenema (100 mg/60Ml) 100 mg/enm Enema6.96USD enema
Proctofoam-hc foam6.77USD g
Cortifoam 10 % Foam6.14USD g
Hycort (100 mg/60Ml) 100 mg/enm Enema5.79USD enema
Cortamed 2.5 % Ointment5.67USD g
Hydrocortisone Sod. Succinate 500 mg/vial5.34USD vial
Hydrocortisone powder5.19USD g
Solu-cortef (pf) 100 mg vial4.85USD vial
Solu-cortef 100 mg vial4.63USD vial
Proctocort 1% cream4.37USD g
Pandel 0.1% cream4.34USD g
Locoid 0.1% lipocream4.3USD g
Solu-Cortef 100 mg/vial4.07USD vial
Locoid 0.1% cream3.92USD g
Hydrocortisone Sod. Succinate 250 mg/vial3.56USD vial
Hydrocortisone ss 250 mg vial3.5USD vial
Anusol-hc 2.5% cream3.45USD g
Hydrocortisone acet powder3.15USD g
Proctofoam2.89USD g
A-hydrocort 100 mg vial2.42USD each
Proctocream-hc 2.5% cream2.17USD g
Hydrocortisone Sod. Succinate 100 mg/vial2.1USD vial
Hydrocortisone val 0.2% cream2.07USD g
Hytone 2.5% cream1.46USD g
Hydrocortisone buty 0.1% cream1.31USD g
First hydrocort 10% gel1.18USD g
Westcort 0.2% cream1.17USD g
Procto-kit 1% cream1.08USD g
Ala-scalp hp 2% lotion1.03USD ml
Cortef 20 mg tablet0.9USD tablet
Proctosol-hc 2.5% cream0.89USD g
Proctozone-hc 2.5% cream0.83USD g
Orabase plain paste0.77USD g
Hydrocortisone 2.5% lotion0.6USD ml
Cortef 10 mg tablet0.55USD tablet
Orabase-b 20% gel0.55USD g
Hydrocortisone 2.5% cream0.53USD g
Hydrocortisone 10 mg tablet0.52USD tablet
Cortef 5 mg tablet0.45USD tablet
Ala-cort 1% cream0.43USD g
Hydrocortisone 5 mg tablet0.38USD tablet
Corticaine 0.5% cream0.37USD g
Hydrocortisone 20 mg tablet0.32USD tablet
Prevex Hc 1 % Occlusive Cream0.3USD g
Emo-Cort 2.5 % Cream0.26USD g
Preparation h 1% cream0.24USD g
Tucks hydrocortisone ointment0.24USD g
Emo-Cort 2.5 % Lotion0.23USD g
Emo-Cort Scalp 2.5 % Lotion0.22USD g
Colocort 100 mg enema0.21USD ml
Cortenema 100 mg enema0.21USD ml
Sarna Hc 2.5 % Lotion0.2USD g
Emo-Cort 1 % Cream0.19USD g
Balneol lotion0.18USD ml
Emo-Cort 1 % Lotion0.18USD g
Lanacort 1% cool creme0.18USD g
Hyderm 0.5 % Cream0.18USD g
Hytone 1% cream0.17USD g
Cortoderm Mild 0.5 % Ointment0.15USD g
Beta hc 1% lotion0.14USD ml
Cortizone-10 1% spray0.14USD ml
Hydroval 0.2 % Cream0.13USD g
Hydroval 0.2 % Ointment0.13USD g
Aquanil hc 1% lotion0.12USD ml
Hydrocortisone plus 12 1% crm0.12USD g
Scalpicin 3% liquid0.12USD ml
Slender cortisol capsule0.12USD capsule
Cortaid 1% spray0.1USD ml
Sarna Hc 1 % Lotion0.1USD g
Hydrocortisone 0.5% cream0.08USD g
Hydrocortisone 1% cream0.08USD g
Uniderm moisturizer0.05USD ml
Cortoderm Regular 1 % Ointment0.04USD g
Hyderm 1 % Cream0.04USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5635497No1994-06-032014-06-03Us
US7378405No2006-12-192026-12-19Us
US7981877No2005-01-232025-01-23Us
USRE39264No1996-08-022016-08-02Us
US6514980No1999-01-242019-01-24Us
US7223387No2001-07-242021-07-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220 °CPhysProp
water solubility320 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.61HANSCH,C ET AL. (1995)
logS-2.97ADME Research, USCD
Caco2 permeability-4.66ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.199 mg/mLALOGPS
logP1.79ALOGPS
logP1.28ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.4 m3·mol-1ChemAxon
Polarizability39.55 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (2.96 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 MEOX; 3 TMS)GC-MSsplash10-0f7o-3930000000-b7b43b2fc9f20acfd20b
GC-MS Spectrum - GC-MSGC-MSsplash10-0f7o-3930000000-b7b43b2fc9f20acfd20b
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-052f-2910000000-2625335a031486ecb302
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-IT , negativeLC-MS/MSsplash10-015a-0189000000-61afe49a8d4a96aae3f9
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-00lu-0149000000-b95a11b27f7e7d44dd51
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-001l-0019000000-4c4924e6ac472ad52886
MS/MS Spectrum - , negativeLC-MS/MSsplash10-001j-0259000000-fda4e876e9ef04015946
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0009000000-cc8188e19dbdd6210b77
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-07r1-1985000000-b6d756bd554367393be3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00dj-1930000000-120dc8893cc4709c1f6b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00dm-2910000000-d1f01e1bce5fe0108f40
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05tf-3900000000-4ffd79c22013fe5479b6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-054o-4900000000-fdbed869a0cadc21b64b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002f-7900000000-dac7b2c5b3f8e8b85086
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016u-7900000000-3a770c3819f82ea45841
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016r-9800000000-d261cf7141fbf30715f5
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-056r-0289000000-9a48511b5c3d5fa404e9
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0759000000-b337a46ecfd6de91776b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05fs-3940000000-2bf712a915c3a2c100a2

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 4 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
show 16 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo steroid, 11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 21-hydroxy steroid, C21-steroid (CHEBI:17650) / Pregnane and derivatives [Fig], Glucocorticoids, C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C00735) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030001)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
  2. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953]
  3. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198]
  4. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
  5. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Structural molecule activity
Specific Function
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Play...
Gene Name
ANXA1
Uniprot ID
P04083
Uniprot Name
Annexin A1
Molecular Weight
38713.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sato-Matsumura KC, Matsumura T, Nakamura H, Sawa H, Nagashima K, Koizumi H: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res. 2000 Oct;292(10):496-9. [PubMed:11142771]
  4. White MV, Igarashi Y, Lundgren JD, Shelhamer J, Kaliner M: Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol. 1991 Jul 15;147(2):667-73. [PubMed:1712816]
  5. Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72. [PubMed:8060156]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation...
Gene Name
HSD11B2
Uniprot ID
P80365
Uniprot Name
Corticosteroid 11-beta-dehydrogenase isozyme 2
Molecular Weight
44126.06 Da
References
  1. Furstenberger C, Vuorinen A, Da Cunha T, Kratschmar DV, Saugy M, Schuster D, Odermatt A: The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012 Apr;126(2):353-61. doi: 10.1093/toxsci/kfs022. Epub 2012 Jan 23. [PubMed:22273746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid delta-isomerase activity
Specific Function
3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system pl...
Gene Name
HSD3B1
Uniprot ID
P14060
Uniprot Name
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
Molecular Weight
42251.25 Da
References
  1. Bhatia C, Oerum S, Bray J, Kavanagh KL, Shafqat N, Yue W, Oppermann U: Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25. doi: 10.1016/j.cbi.2014.12.013. Epub 2014 Dec 16. [PubMed:25526675]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Khoromi S, Muniyappa R, Nackers L, Gray N, Baldwin H, Wong KA, Matheny LA, Moquin B, Rainer A, Hill S, Remaley A, Johnson LL, Max MB, Blackman MR: Effects of chronic osteoarthritis pain on neuroendocrine function in men. J Clin Endocrinol Metab. 2006 Nov;91(11):4313-8. Epub 2006 Aug 15. [PubMed:16912126]
  2. Stroud LR, Solomon C, Shenassa E, Papandonatos G, Niaura R, Lipsitt LP, Lewinn K, Buka SL: Long-term stability of maternal prenatal steroid hormones from the National Collaborative Perinatal Project: still valid after all these years. Psychoneuroendocrinology. 2007 Feb;32(2):140-50. Epub 2007 Jan 31. [PubMed:17270355]
  3. Lombardi G, Mondaini N, Macchiarella A, Del Popolo G: Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients. J Androl. 2007 Sep-Oct;28(5):722-6. Epub 2007 May 9. [PubMed:17494102]
  4. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA: A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007 Nov-Dec;14(6):985-94. [PubMed:17507833]
  5. Rizzo L, Dobrovsky V, Danilowicz K, Kral M, Cross G, Serra HA, Bruno OD: Low-dose glucocorticoids in hyperandrogenism. Medicina (B Aires). 2007;67(3):247-52. [PubMed:17628912]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Henley DE, Lightman SL: New insights into corticosteroid-binding globulin and glucocorticoid delivery. Neuroscience. 2011 Apr 28;180:1-8. doi: 10.1016/j.neuroscience.2011.02.053. Epub 2011 Mar 1. [PubMed:21371536]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  2. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]
  3. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]
  4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010]
  5. Orlowski S, Mir LM, Belehradek J Jr, Garrigos M: Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J. 1996 Jul 15;317 ( Pt 2):515-22. [PubMed:8713080]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18